Abstract: Objective: As a novel oral agent in treating anemia of chronic kidney disease (CKD), several clinical trials of vadadustat have been conducted to compare with darbepoetin alfa. This study systematically reviews and investigates the efficacy and safety of vadadustat in the anemia treatment with different duration in both nondialysis-dependent CKD (NDD-CKD) and dialysis-dependent CKD (DD-CKD).
Methods: Several main databases were searched for randomized controlled trials (RCTs) reporting vadadustat vs darbepoetin alfa for anemia patients with CKD. The outcome indicators were focused on hemoglobin (Hb), the percentage of patients within the target Hb, the need for RBC (Red Blood Cell) transfusions, and serious adverse events (SAEs).
Results: Four eligible studies with 8,026 participants were included. The changes of Hb levels from the baseline in the darbepoetin alfa group were significantly higher than that in the vadadustat group with DD-CKD (mean difference (MD) - 0.19, [95% confidence interval (CI), - 0.21 to - 0.17], p < 0.0001). In NDD-CKD patients, the changes of Hb levels in the two groups are not significantly different (MD = - 0.06, [95% CI, - 0.18 to 0.05], p = 0.006), especially, during the treatment duration of 20-36 weeks (MD = 0.02, [95% CI, - 0.04 to 0.08], p = 0.51). The percentage of patients within the target Hb was significantly lower in the vadadustat group than that in the darbepoetin alfa group in DD-CKD patients (MD = 0.9, [95% CI, 0.86 to 0.94], p < 0.00001), while in NDD-CKD patients, there was no significant difference (MD = 1.05, [95% CI, 0.99 to 1.12], p < 0.00001). In terms of safety, the two agents had no significant difference in the incidence of RBC transfusions and SAEs (RR = 1.26 [95% CI, 0.99 to 1.61], p = 0.52; RR = 0.97, [95% CI, 0.94 to 1.01], p = 0.19; respectively).
Conclusion: Compared to darbepoetin alfa, vadadustat had the same effect in raising the hemoglobin level in NDD-CKD patients in the short term. Vadadustat may become an effective and safe alternative for the treatment of patients with anemia and CKD, especially in NDD-CKD patients. As the application of vadadustat is still under exploration, future research should compensate for the limitations of our study to estimate the vadadustat's value.
(© 2022. The Author(s), under exclusive licence to Springer Nature B.V.)
References: Foundation NK II (2006) Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 47:S16-85. (PMID: 10.1053/j.ajkd.2006.03.011)
Akizawa T, Okumura H, Alexandre A, Fukushima A, Kiyabu G, Dorey J (2018) Burden of anemia in chronic kidney disease patients in japan: a literature review. Ther Apheresis Dial 22:444–456. (PMID: 10.1111/1744-9987.12712)
van Haalen H, Jackson J, Spinowitz B, Milligan G, Moon R (2020) Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data. BMC Nephrol 21:88. (PMID: 10.1186/s12882-020-01746-4)
Szczech L, Barnhart H, Inrig J et al (2008) Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74:791–798. (PMID: 10.1038/ki.2008.295)
Koulouridis I, Alfayez M, Trikalinos T, Balk E, Jaber B (2013) Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 61:44–56. (PMID: 10.1053/j.ajkd.2012.07.014)
Suresh S, Wright E, Wright D, Abbott K, Noguchi C (2021) Erythropoietin treatment and the risk of hip fractures in hemodialysis patients. J Bone Mineral Res 36:1211–1219. (PMID: 10.1002/jbmr.4297)
Hurst JH (2016) William Kaelin, Peter Ratcliffe, and Gregg Semenza receive the 2016 Albert Lasker Basic Medical Research Award. J Clin Investig 126:3628–3638. (PMID: 10.1172/JCI90055)
Fandrey J, Schödel J, Eckardt K-U, Katschinski DM, Wenger RH (2019) Now a Nobel gas: oxygen. Pflügers Archiv-Eur J Physiol 471:1343–1358. (PMID: 10.1007/s00424-019-02334-8)
Semenza GL (2011) Oxygen sensing, homeostasis, and disease. N Engl J Med 365:537–547. (PMID: 10.1056/NEJMra1011165)
Schödel J, Ratcliffe PJ (2019) Mechanisms of hypoxia signalling: new implications for nephrology. Nat Rev Nephrol 15:641–659. (PMID: 10.1038/s41581-019-0182-z)
Hartman C, Smith MT, Flinn C et al (2011) AKB-6548, a new hypoxia-inducible factor prolyl hydroxylase inhibitor increases hemoglobin while decreasing ferritin in a 28-day, phase 2a dose escalation study in stage 3 and 4 chronic kidney disease patients with anemia. J Am Soc Nephrol 22:435A.
Yeh T-L, Leissing TM, Abboud MI et al (2017) Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials. Chem Sci 8:7651–7668. (PMID: 10.1039/C7SC02103H)
Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH (2016) Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int 90:1115–1122. (PMID: 10.1016/j.kint.2016.07.019)
Martin ER, Smith MT, Maroni BJ, Zuraw QC, de Goma EM (2017) Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am J Nephrol 45:380–388. (PMID: 10.1159/000464476)
Nangaku M, Farag YM, de Goma E, Luo W, Vargo D, Khawaja Z (2021) Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrol Dial Transplant 36:1244–1252. (PMID: 10.1093/ndt/gfaa060)
Nangaku M, Kondo K, Kokado Y et al (2021) Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. J Am Soc Nephrol 32(7):1779–1790. (PMID: 10.1681/ASN.2020091311)
Eckardt K-U, Agarwal R, Aswad A et al (2021) Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N Engl J Med 384:1601–1612. (PMID: 10.1056/NEJMoa2025956)
Chertow GM, Pergola PE, Farag YM et al (2021) Vadadustat in patients with anemia and non–dialysis-dependent CKD. N Engl J Med 384:1589–1600. (PMID: 10.1056/NEJMoa2035938)
Nangaku M, Kondo K, Ueta K et al (2021) Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study. Nephrol Dial Transplant 36(9):1731–1741. (PMID: 10.1093/ndt/gfab055)
Markham A (2020) Vadadustat: first approval. Drugs 80(1):85–90. (PMID: 10.1007/s40265-019-01251-5)
Wish JB (2021) Treatment of anemia in kidney disease: beyond erythropoietin. Kidney Int Rep 6(10):2540–2553. (PMID: 10.1016/j.ekir.2021.05.028)
Singh AK, Szczech L, Tang KL et al (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098. (PMID: 10.1056/NEJMoa065485)
Food U, Administration D, Health UDo, Services H (2011) FDA Drug Safety Communication: Modified Dosing Recommendations to Improve the Safe Use of Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease. Safety Announcement 6:24.
Sakaguchi Y, Hamano T, Wada A, Masakane I (2019) Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis. J Am Soc Nephrol 30:1037–1048. (PMID: 10.1681/ASN.2018101007)
Zheng Q, Wang Y, Yang H et al (2020) Efficacy and safety of daprodustat for anemia therapy in chronic kidney disease patients: a systematic review and meta-analysis. Front Pharmacol. https://doi.org/10.3389/fphar.2020.573645. (PMID: 10.3389/fphar.2020.573645)
Tang M, Zhu C, Yan T, Zhou Y, Lv Q, Chuan J (2021) Safe and effective treatment for anemic patients with chronic kidney disease: an updated systematic review and meta-analysis on roxadustat. Front Pharmacol 12:1676. (PMID: 10.3389/fphar.2021.658079)
Putra B, Putra F (2021) POS-285 Expangding the potential benefit of hypoxia-inducible factor prolyl hydroxylase inhibitors for improving dyslipidemia in anemia of chronic kidney disease patients: meta-analusis of randomized controlled trials. Kidney Int Rep 6:S121–S122. (PMID: 10.1016/j.ekir.2021.03.300)
Gupta N, Wish JB (2017) Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis 69:815–826. (PMID: 10.1053/j.ajkd.2016.12.011)
Processing Request
No Comments.